Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance.

Lambein K, Van Bockstal M, Vandemaele L, Geenen S, Rottiers I, Nuyts A, Matthys B, Praet M, Denys H, Libbrecht L.

Am J Clin Pathol. 2013 Oct;140(4):561-6. doi: 10.1309/AJCP4A7KTAYHZSOE.

2.

Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.

Clay MR, Iberri DJ, Bangs CD, Cherry A, Jensen KC.

Am J Surg Pathol. 2013 Jan;37(1):120-7. doi: 10.1097/PAS.0b013e31826ab19d.

PMID:
23108020
3.

Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.

Yosepovich A, Avivi C, Bar J, Polak-Charcon S, Mardoukh C, Barshack I.

Isr Med Assoc J. 2010 Jun;12(6):353-6.

4.

Dual HER2 gene protein assay: focused study of breast cancers with 2+ immunohistochemical expression.

Li Z, Dabbs DJ, Cooper KL, Bhargava R.

Am J Clin Pathol. 2015 Mar;143(3):451-8. doi: 10.1309/AJCPKIVVW4OBPX6I.

5.

Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.

Gunn S, Yeh IT, Lytvak I, Tirtorahardjo B, Dzidic N, Zadeh S, Kim J, McCaskill C, Lim L, Gorre M, Mohammed M.

BMC Cancer. 2010 Jul 28;10:396. doi: 10.1186/1471-2407-10-396.

6.

Expression profiling of breast tumors based on human epidermal growth factor receptor 2 status defines migration-related genes.

Cuadros M, Cano C, López FJ, López-Castro R, Concha A.

Pathobiology. 2013;80(1):32-40. doi: 10.1159/000339431. Epub 2012 Jul 24.

PMID:
22832278
7.

Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.

Shah SS, Ketterling RP, Goetz MP, Ingle JN, Reynolds CA, Perez EA, Chen B.

Hum Pathol. 2010 Jan;41(1):103-6. doi: 10.1016/j.humpath.2009.07.001. Epub 2009 Sep 16.

PMID:
19762065
8.

HER2 testing of multifocal invasive breast carcinoma: how many blocks are enough?

Bethune GC, Mullen JB, Chang MC.

Am J Clin Pathol. 2013 Oct;140(4):588-92. doi: 10.1309/AJCPZSV2W1CPGRJW.

9.

[Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].

Zhang GH, Shi DR, Liang XM, Hou JH, Kang SY, Zhu WD, Li XB, Shao Y, Chen LR, Zhou Y.

Zhonghua Bing Li Xue Za Zhi. 2006 Oct;35(10):580-3. Chinese.

PMID:
17134562
10.

High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system.

Gown AM, Goldstein LC, Barry TS, Kussick SJ, Kandalaft PL, Kim PM, Tse CC.

Mod Pathol. 2008 Oct;21(10):1271-7. doi: 10.1038/modpathol.2008.83. Epub 2008 May 16.

11.

HER2 testing in breast cancer: NCCN Task Force report and recommendations.

Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM; NCCN HER2 Testing in Breast Cancer Task Force.

J Natl Compr Canc Netw. 2006 Jul;4 Suppl 3:S1-22; quiz S23-4. Review.

PMID:
16813731
12.

HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry.

Kovács A, Stenman G.

Pathol Res Pract. 2010 Jan 15;206(1):39-42. doi: 10.1016/j.prp.2009.08.003. Epub 2009 Oct 12.

PMID:
19819642
13.

[Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].

Zeng X, Liang ZY, Wu SF, Zhou WX, Gao J, Liu TH.

Zhonghua Bing Li Xue Za Zhi. 2006 Oct;35(10):584-8. Chinese.

PMID:
17134563
14.

[Analysis of HER2 status in breast carcinoma using fully automated HER2 staining and fluorescence in-situ hybridization technology].

Ying JM, Liu XY, Guo L, Xie YQ, Lü N.

Zhonghua Bing Li Xue Za Zhi. 2012 May;41(5):296-300. doi: 10.3760/cma.j.issn.0529-5807.2012.05.003. Chinese.

PMID:
22883666
15.

Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.

Kuo SJ, Wang BB, Chang CS, Chen TH, Yeh KT, Lee DJ, Yin PL, Chen M.

Taiwan J Obstet Gynecol. 2007 Jun;46(2):146-51.

16.
18.

Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.

Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF.

J Clin Oncol. 2005 Jul 1;23(19):4287-97.

19.

Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.

Arihiro K, Oda M, Ogawa K, Tominaga K, Kaneko Y, Shimizu T, Matsumoto S, Oda M, Kurita Y, Taira Y.

Jpn J Clin Oncol. 2013 Jan;43(1):55-62. doi: 10.1093/jjco/hys187. Epub 2012 Dec 7.

20.

Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast.

Lee AH, Key HP, Bell JA, Hodi Z, Ellis IO.

Histopathology. 2012 May;60(6):880-4. doi: 10.1111/j.1365-2559.2011.04144.x. Epub 2012 Feb 9.

PMID:
22320892
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk